Sir, my first question is on the fluoropolymers business. Generally, chemicals business excluding EV. So in the past, we said our steady-state targets for the existing assets and capacity at a much higher level. But now we are saying that we have not even reached 80 percentage of that, but still we are seeing that we are fully utilized and we would like to add c apex. So how should we look at this? Was it any expectation of ours didn't happen because we are not able to ramp up or what's happening around in this fluoropolymers and new fluoropolymer business?
Actually, what I meant was not with respect to the product approval time lines, but we understand that it's fairly longer gestation period products. But what I am trying to ask is, is this the kind of EBITDA numbers for the fluoropolymers at least in the chemical business, is this a steady state number that we actually envisaged when we put up those plants 2 years ago o r is it something like lower than what we envisaged?